Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALTNASDAQ:GMTXNASDAQ:MORNASDAQ:OPHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AGMTXGemini Therapeutics$54.75+3.0%$49.16$1.16▼$14.10$2.37B-0.12189,291 shs218,300 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AOPHTIVERIC bio$1.30$1.02▼$4.50$1.65B1.49159,109 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+1.39%GMTXGemini Therapeutics+3.99%-1.38%+11.40%+16.17%+27.75%MORMorphoSys0.00%0.00%0.00%0.00%+4.18%OPHTIVERIC bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/AOPHTIVERIC bioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AGMTXGemini Therapeutics 0.00N/AN/AN/AMORMorphoSys 0.00N/AN/AN/AOPHTIVERIC bio 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17OPHTIVERIC bio$209.98M0.00N/AN/A$3.00 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AOPHTIVERIC bio$63.09M-$1.67N/AN/AN/AN/A-141.53%-41.88%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AOPHTIVERIC bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59GMTXGemini TherapeuticsN/A71.4971.49MORMorphoSys4.981.381.38OPHTIVERIC bioN/A10.0910.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%GMTXGemini Therapeutics75.42%MORMorphoSys18.38%OPHTIVERIC bio45.39%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%GMTXGemini Therapeutics12.90%MORMorphoSys0.05%OPHTIVERIC bio3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableOPHTIVERIC bio3541.42 millionN/AOptionableOPHT, MOR, GMTX, and CALT HeadlinesRecent News About These CompaniesGossamer Bio Inc GOSSNovember 5, 2023 | morningstar.comMIveric Bio releases 24-month topline results from Phase 3 study of avacincaptad pegol intravitreal solution (IZERVAY) for geographic atrophySeptember 19, 2023 | ophthalmologytimes.comOAstellas-bought Iveric gains FDA clearance for eye drug IzervayAugust 8, 2023 | bioworld.comBIveric Gets FDA Approval in Geographic Atrophy After Being Acquired by AstellasAugust 7, 2023 | biospace.comBAstellas Pharma closes $5.9B acquisition of Iveric BioJuly 13, 2023 | njbiz.comNIveric Bio ticks higher as it sees sale to Astellas closing July 11June 29, 2023 | msn.comIveric Bio falls amid concern about Astellas dealJune 29, 2023 | msn.comAstellas to acquire Iveric Bio for approximately $5.9bnMay 13, 2023 | pmlive.comPJapan's Astellas Pharma agrees to buy Iveric Bio for $5.9 blnMay 7, 2023 | health.economictimes.indiatimes.comBaird Downgrades IVERIC bio (ISEE)May 6, 2023 | msn.comApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioMay 6, 2023 | msn.comOphthalmology specialist Iveric snapped up by Astellas for $5.9 billionMay 3, 2023 | outsourcing-pharma.comOAstellas forks out $5.9bn to buy Iveric BioMay 3, 2023 | bioprocessintl.comBAstellas eyes ophthalmology field with $5.9B Iveric Bio takeoverMay 2, 2023 | labiotech.euLIveric Bio (NASDAQ:ISEE) Sold for $5.9BMay 1, 2023 | msn.comAstellas buying Iveric Bio for $5.9B to build ophthalmology franchiseMay 1, 2023 | bioworld.comBAstellas to Acquire Iveric Bio for $5.9B, Expanding Eye Disease PipelineMay 1, 2023 | genengnews.comGAstellas to Buy Eye-Drug Maker Iveric Bio for $5.9 BillionMay 1, 2023 | msn.comEying Its Next Blockbuster, Astellas Lines Up $5.9B Iveric Bio AcquisitionMay 1, 2023 | medcitynews.comMAstellas acquires Iveric Bio for $5.9B, entering competition to treat common cause of vision lossMay 1, 2023 | statnews.comSMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Stocks Set to Double—And There's Still Time to BuyBy Nathan Reiff | June 12, 2025View 3 Stocks Set to Double—And There's Still Time to BuyMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for Outperformance3 Stocks Hitting All-Time Highs With More Room to RunBy Dan Schmidt | June 27, 2025View 3 Stocks Hitting All-Time Highs With More Room to RunWhy Hims & Hers Stock Could Be a Multi-Bagger in the MakingBy Gabriel Osorio-Mazilli | June 24, 2025View Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingBig Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadOPHT, MOR, GMTX, and CALT Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 07/3/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Gemini Therapeutics NASDAQ:GMTX$54.75 +1.58 (+2.97%) As of 07/3/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/3/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.IVERIC bio NASDAQ:OPHTIVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
